{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-030561","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2026-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.260959+00:00","generated_at":"2026-05-16T06:03:02.720711+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ALX reports $48.3M cash; CD47 predictive of evorpacept response in HER2+ breast cancer Phase 1b/2","bullets":["Preliminary cash, cash equivalents, and investments total $48.3M as of Dec 31, 2025.","Phase 1b/2 trial data show CD47 expression is predictive of evorpacept response in HER2+ metastatic breast cancer.","In 9 confirmed HER2+ patients, cORR was 56% (5/9) with median PFS of 7.4 months (prior SABCS2024 data).","Full biomarker analysis submitted for presentation at an upcoming scientific conference.","Results align with ASPEN-06 gastric cancer trial, strengthening confidence in ongoing ASPEN-09-Breast Phase 2 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-030561","json":"https://secwatch.observer/filing/0001193125-26-030561.json","markdown":"https://secwatch.observer/filing/0001193125-26-030561.md","text":"https://secwatch.observer/filing/0001193125-26-030561.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526030561/0001193125-26-030561-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526030561/d68428d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:03:02.720711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}